RJA
TNYA icon

Raymond James & Associates’s Tenaya Therapeutics TNYA Stock Holding History

Raymond James & Associates’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,000
Closed -$58.7K – 3940
2023
Q2 		$58.7K Buy
+10,000
New +$58.1K ﹤0.01% 3692

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Raymond James & Associates's TNYA Position: Q3 2023 in Review

Raymond James & Associates sold out of Tenaya Therapeutics (TNYA) in Q3 2023, closing a stake of 10,000 shares — an estimated $58.7K sold.

Raymond James & Associates first reported a position in TNYA in Q2 2023 and held it in 1 quarter. The position peaked at $58.7K in Q2 2023. 76 funds tracked by Wall St. Rank hold TNYA as of Q3 2023.

  • Raymond James & Associates reported no remaining Tenaya Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Raymond James & Associates sold 10,000 Tenaya Therapeutics shares in Q3 2023, an estimated $58.7K.
  • Raymond James & Associates first reported a position in Tenaya Therapeutics in Q2 2023 and held it in 1 quarter.
  • Raymond James & Associates's Tenaya Therapeutics position peaked at $58.7K in Q2 2023.
  • 76 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.